Translations:GLP-1 receptor agonist/14/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 21:59, 5 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (GLP-1 receptor agonist)
==Adverse effects==
The most common adverse effects of GLP-1 agonists are gastrointestinal. These adverse effects limit the maximum tolerated dose and require gradual [[dose escalation]]. Nausea is directly related to the serum concentration of the GLP-1 agonist and is more commonly reported, in up to three-quarters, of people using short-acting GLP-1 agonists but fewer of those using long-acting agonists. Reactions at the injection site are also common, especially with shorter acting drugs.

Adverse effects

The most common adverse effects of GLP-1 agonists are gastrointestinal. These adverse effects limit the maximum tolerated dose and require gradual dose escalation. Nausea is directly related to the serum concentration of the GLP-1 agonist and is more commonly reported, in up to three-quarters, of people using short-acting GLP-1 agonists but fewer of those using long-acting agonists. Reactions at the injection site are also common, especially with shorter acting drugs.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:GLP-1_receptor_agonist/14/en&oldid=110964"